Loading…
Employees: 35
Size Fennec Pharmaceuticals (FENC) is a United States Health Care company (Biotechnology) with a market value of $344M, the 2997th largest of 3,117 United States companies the cockpit tracks. Shares closed at $9.81 on 6 Nov 2026.
Performance Over six months the shares gained 41.6%, against -28.2% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 18 in its peer set.
Growth Revenue grew 77.8% over the last twelve months (peer median -26.9%); the operating margin is -2.7% (peer median -554.7%).
Valuation It trades at 18.7× forward earnings.
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $59.2M | $44.6M | $47.5M | $21.3M | $1.53M |
| Revenue growth | — | -6% | +124% | +1,284% | — |
| Gross profit | $55.5M | $40.9M | $44.4M | $20.0M | $1.45M |
| EBITDA | -$1.54M | -$6.28M | $2.57M | -$12.8M | -$22.6M |
| Net income | -$3.61M | -$9.74M | -$436,000 | -$16.0M | -$23.7M |
| Free cash flow | -$3.89M | -$14.4M | $27.0M | -$17.1M | -$18.1M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $18.1M | $29.7M | $24.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FENC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.7% | -17.2% | 8th highest of 20 |
| 6-month return | +41.6% | -28.2% | 3rd highest of 18 |
| Distance from 52-week high | -26.0% | -56.0% | 2nd highest of 20 |
| Revenue growth (TTM) | +77.8% | -26.9% | 3rd highest of 15 |
| Operating margin | -2.7% | -554.7% | 4th highest of 16 |
| Forward P/E | 18.7× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 18.7× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | n/a | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | n/a | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | n/a | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 9.5× | 5.6% | +19.1% |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 11.4× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $328M | -57% | n/a | -57% | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $325M | n/a | +395% | -173% | n/a | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | n/a | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | n/a | n/a | n/a |
| TransThera Sciences (Nanjing) 2617.HK | Hong Kong | $323M | -83% | n/a | -751% | n/a | n/a | n/a |
| Agenus AGEN | United States | $323M | +87% | +30% | 27% | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | n/a | n/a | n/a |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -555% | n/a | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |